Nuveen Asset Management, LLC Contrafect Corp Transaction History

Nuveen Asset Management, LLC

  • $345 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 16, 2021
SELL
$3.58 - $4.9 $301,092 - $412,109
-84,104 Closed
0 $0
Q1 2021

May 17, 2021
SELL
$4.46 - $6.68 $128,613 - $192,631
-28,837 Reduced 25.53%
84,104 $403,000
Q4 2020

Feb 16, 2021
BUY
$5.05 - $6.4 $4,191 - $5,312
830 Added 0.74%
112,941 $570,000
Q3 2020

Nov 16, 2020
BUY
$5.05 - $6.99 $255,843 - $354,127
50,662 Added 82.45%
112,111 $592,000
Q2 2020

Aug 14, 2020
BUY
$4.69 - $7.81 $288,195 - $479,916
61,449 New
61,449 $392,000

Others Institutions Holding CFRX

# of Institutions
2
Shares Held
49.2K
Call Options Held
0
Put Options Held
0
View Full List

About CONTRAFECT Corp

CFRX Quotes by TradingView
  • Ticker CFRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,332,700
  • Market Cap $1.18M
  • Description
  • ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus...
More about CFRX
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email